Symbiotec Pharmalab IPO

About Symbiotec Pharmalab IPO

The IPO of Symbiotec Pharmalab comprises a fresh issue and an offer for sale. The fresh issue aggregates up to ₹150 crores, while the offer for sale aggregates up to ₹2030 crores. The price band is ₹[TBA] per share.

Symbiotec Pharmalab IPO opens on [TBA] and closes on [TBA]. The allotment of shares will take place on [TBA]. The credit of shares to the Demat account will take place on [TBA]. The initiation of refunds will take place on [TBA]. The listing of shares will take place on [TBA].

The lot size of shares in the IPO is [TBA]. The minimum number of lots in the IPO for retail investors is [TBA]. The minimum investment amount required by a retail investor is ₹[TBA] based on the upper price.

Symbiotec Pharmalab is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms- organic chemistry, biotechnology and complex injectables.

Objectives of Symbiotec Pharmalab IPO

The company proposes to utilise the net proceeds received for:

• Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company
  
• General corporate purposes
  

Industry Outlook

The global pharmaceutical market is poised for sustained expansion, propelled by a confluence of structural demand drivers and ongoing innovation. As populations age and the burden of chronic diseases intensifies, healthcare systems worldwide are witnessing increased demand for effective, accessible, and long-term treatment solutions.

In this evolving landscape, the global pharmaceutical market is expected to grow at a CAGR of 6.4% between 2024 and 2029, surpassing the 5.2% growth recorded from 2019 to 2024, and reaching USD 2.1 trillion by 2029.

On the other hand, injectables recorded an 8.5% growth rate from 2019 to 2024 and are projected to grow at a 9.3% CAGR, reaching USD 448.6 billion by 2029, up from USD 674.4 billion in 2024.

Symbiotec Pharmalab Company Information

Symbiotec Pharmalab is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms- organic chemistry, biotechnology and complex injectables.

It has a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (“APIs”) in volume terms in Fiscal 2025, with a global volume market share of 36.2% in corticosteroid and 44.2% in steroidal-hormone APIs.

Strengths of Symbiotec Pharmalab

• Global leadership in corticosteroid and steroidal-hormone APIs
• Long-standing relationships with domestic and global customer base
• Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record
• Continuous investment in R&D, with leading technological capabilities among Indian peers
• Ability to leverage science and existing competencies to increase total addressable market and deepen intellectual property-driven offerings
• Robust financials with strong gross margins, high capital efficiency and cash conversion
• Seasoned leadership team supported by strong pool of experienced management and marquee investors

Risks of Symbiotec Pharmalab

• Reduction in demand for APIs, and top products in particular, could have an adverse effect on business
• Any manufacturing or quality control failures may subject the company to regulatory action
• Inability to handle risks associated with export sales could adversely affect sales to customers
• Imposition of tariffs or other anti-outsourcing legislation by the United States could adversely affect results of operations, financial condition and cash flows
• Loss of relationship with key customers or delays or reductions in their orders could have an adverse effect on business
• Slowdown, interruption or shutdown in manufacturing operations in Madhya Pradesh could have an adverse effect on business and results of operations
• Loss of suppliers or non-performance of their obligations could adversely affect business
• Success depends on the ability to develop and commercialise new products in a timely manner. Any failure to do so can affect the business adversely.
• Operations involve activities and materials which are hazardous in nature and could result in a suspension of operations
• Subject to extensive regulation from governmental and international authorities

Anchor Investor Bidding Date TBA

IPO Registrar and Book Running Lead Managers

• IPO Registrar: MUFG Intime India
• Book Running Lead Managers: JM Financial, Avendus Capital, Motilal Oswal Investment

Advisors and Nomura Financial Advisory and Securities (India)

Symbiotec Pharmalab Business Model

The capabilities of Symbiotec Pharmalab spans three interlinked platforms: (i) organic chemistry, including flow chemistry, hydrogenation, and photochemistry; (ii) biotechnology, including biosynthesis and biotransformation, and recombinant biologics, including Glucagon-like Peptide-1 (“GLP-1”) and Insulins; and (iii) forward integration into complex injectables including double-chamber vials, double-chamber bags and double-chamber syringes, collectively enabling it to commercialise and scale hard-to-replicate products and services.

Symbiotec Pharmalab Growth Trajectory

The revenue from operations of Symbiotec Pharmalab increased from ₹566.514 crores in FY 23 to ₹751.554 crores in FY 25. Its EBITDA margin increased from 12.96% in FY 23 to 27.26% in FY 25, while PAT margin increased from 4.10% in FY 23 to 12.80% in FY 25. Global leadership in corticosteroid and steroidal-hormone APIs and long-standing relationships with domestic and global customer base have helped the company grow over the years.

Symbiotec Pharmalab Market Position

With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated platform with approvals from the United States Food and Drug Administration (“US FDA”), European Union Good Manufacturing Practices (“EU-GMP”), Ministry of Food and Drug Safety, Korea and other global organisations. It’s the only Indian and global company to have a presence across the top 10 corticosteroid and steroidal-hormone APIs in fiscal 2025.

How to Apply for Symbiotec Pharmalab IPO?

To apply for Symbiotec Pharmalab IPO:

• Log in to your Kotak Neo Demat account - Log in to your Demat account to access IPO investments. Next, select the current IPO section.
• Specify IPO details - Enter the number of lots and the price you wish to apply for.
• Enter UPI ID - After entering your UPI ID, click submit. This will place your bid with the exchange.
• Mandate Notification - Your UPI app will receive a mandate notification to block funds.
• Approve Request - Your funds will be blocked once you approve the mandate request on your UPI.